Royalty Pharma plc - Ordinary Shares - Class A Stock

$36.17

0.53%

Nasdaq, Sep 02, 10:00 pm CET

ISIN

GB00BMVP7Y09

Symbol

RPRX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Royalty Pharma plc - Ordinary Shares - Class A Stock price

$36.17

-5.58 13.37% 5Y

Nasdaq, Closing price Tue, Sep 02 2025

+0.19 0.53%

ISIN

GB00BMVP7Y09

Symbol

RPRX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$21.1b

Enterprise Value

$27.6b

Net debt

$6.5b

Cash

$1.5b

Shares outstanding

583.2m

Valuation (TTM | estimate)

P/E

20.0 | 7.9

P/S

9.2 | 7.0

EV/Sales

12.0 | 9.1

EV/FCF

38.7

P/B

3.3

Dividends

DPS

$0.84

Yield 1Y | 5Y

2.3% | 1.8%

Growth 1Y | 5Y

5.0% | -

Payout 1Y | 3Y

58.3% | 70.2%

Increased

5 Years

Financials (TTM | estimate)

Revenue

$2.3b | $3.0b

EBITDA

- | $2.9b

EBIT

$1.8b | $2.7b

Net Income

$1.0b | $2.7b

Free Cash Flow

$713.0m

Growth (TTM | estimate)

Revenue

3.0% | 33.8%

EBITDA

- | 120.9%

EBIT

91.7% | 111.0%

Net Income

51.6% | 211.7%

Free Cash Flow

77.9%

Financial Health

Equity Ratio

38.1%

Return on Equity

12.4%

ROCE

10.8%

ROIC

11.0%

Debt/Equity

1.3

EPS

$1.8

FCF per Share

$1.2

Short interest

3.3%

Employees

Rev per Employee

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Get Started for Free Today

Royalty Pharma plc - Ordinary Shares - Class A Stock Analysis

Unlock Scores for Free

??

13 Analysts have issued a Royalty Pharma plc - Ordinary Shares - Class A forecast:

10x Buy

77%

3x Hold

23%

More details on Analyst Estimates Including Price Targets

13 Analysts have issued a Royalty Pharma plc - Ordinary Shares - Class A forecast:

Buy

77%

Hold

23%

Analyst Estimates with Stock Price Targets

Financial data from Royalty Pharma plc - Ordinary Shares - Class A

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '25		+/- %
Revenue	2,305 2,305	3% 3% 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	507 507	122% 122% 22%
- Research and Development Expense	352 352	577% 577% 15%
EBITDA	- -	- -
- Depreciation and Amortization	- -	- -
EBIT (Operating Income) EBIT	1,841 1,841	92% 92% 80%
Net Profit	1,021 1,021	52% 52% 44%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Royalty Pharma plc - Ordinary Shares - Class A Stock News

Neutral

GlobeNewsWire

●

about 5 hours ago

Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes

NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it has priced an offering of $2.0 billion of senior unsecured notes, comprised of the following (collectively, the “Notes”):

Neutral

GlobeNewsWire

●

about 18 hours ago

Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million

NEW YORK and WALTHAM, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Zenas BioPharma, Inc. (Nasdaq: ZBIO) today announced that Royalty Pharma will provide up to $300 million in funding in exchange for a royalty on sales of obexelimab.

Neutral

GlobeNewsWire

●

about 19 hours ago

Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million

- Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related Disease - - Additional $150 million associated with the upcoming results of the obexelimab Phase 3 INDIGO trial and FDA approval for the treatment of IgG4-Related Disease - WALTHAM, Mass. and New York, Sept.

More Royalty Pharma plc - Ordinary Shares - Class A News

Company Profile

Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The firm's portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, and Vertex’s Kalydeco, Symdeko and Trikafta, and four development-stage product candidates. It focuses on acquiring royalty-generating products segment. The firm invests in biopharmaceutical products. The company was founded by Pablo Gerardo Legorreta in 1996 and is headquartered in New York, NY.

Head office	United Kingdom
CEO	Pablo Legorreta
Founded	1996
Website	www.royaltypharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now